Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...

Blockbuster GLP-1 medications like Ozempic and Wegovy are transforming patient care, altering surgery volumes and redefining the healthcare industry's financial landscape. Beyond weight loss ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...

External USB/Thunderbolt drives (aka direct-attached storage, or DAS) are a super-convenient way to quickly back up your important files, as well as store any data that you don’t need on your ...

In recent years, GLP-1 for weight loss has emerged as a significant breakthrough, capturing the attention of both healthcare providers and individuals struggling with obesity. Glucagon-like peptide-1 ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what the ...

Arizona State Retirement System raised its holdings in Penumbra, Inc. (NYSE:PEN – Free Report) by 1.0% in the fourth quarter, Holdings Channel reports.The firm owned 10,710 shares of the company ...

This article is part of a featured content programme.

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...